Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2020 Apr 28;15(4):e0226657. doi: 10.1371/journal.pone.0226657

Biophysical analysis of Plasmodium falciparum Hsp70-Hsp90 organising protein (PfHop) reveals a monomer that is characterised by folded segments connected by flexible linkers

Stanley Makumire 1, Tawanda Zininga 1,2, Juha Vahokoski 3, Inari Kursula 3,4, Addmore Shonhai 1,*
Editor: Didier Picard5
PMCID: PMC7188212  PMID: 32343703

Abstract

Plasmodium falciparum causes the most lethal form of malaria. The cooperation of heat shock protein (Hsp) 70 and 90 is thought to facilitate folding of select group of cellular proteins that are crucial for cyto-protection and development of the parasites. Hsp70 and Hsp90 are brought into a functional complex that allows substrate exchange by stress inducible protein 1 (STI1), also known as Hsp70-Hsp90 organising protein (Hop). P. falciparum Hop (PfHop) co-localises and occurs in complex with the parasite cytosolic chaperones, PfHsp70-1 and PfHsp90. Here, we characterised the structure of recombinant PfHop using synchrotron radiation circular dichroism (SRCD) and small-angle X-ray scattering. Structurally, PfHop is a monomeric, elongated but folded protein, in agreement with its predicted TPR domain structure. Using SRCD, we established that PfHop is unstable at temperatures higher than 40°C. This suggests that PfHop is less stable at elevated temperatures compared to its functional partner, PfHsp70-1, that is reportedly stable at temperatures as high as 80°C. These findings contribute towards our understanding of the role of the Hop-mediated functional partnership between Hsp70 and Hsp90.

1. Introduction

Heat shock proteins (Hsp) serve primarily as protein folding facilitators. They also participate in several other processes, such as protein transport, assembly/disassembly of protein complexes, protein degradation, amongst others [1]. Their role in the survival and pathogenicity of malaria parasites is increasingly becoming apparent [2, 3, 4]. Plasmodium falciparum is the agent for the most lethal form of malaria. It has been reported that the cytosolic P. falciparum heat shock protein 70–1 (PfHsp70-1) is cyto-protective due to its ability to suppress protein mis-folding and aggregation under stressful conditions [5, 6]. In addition, another cytosolic molecular chaperone, P. falciparum Hsp90 (PfHsp90) is essential [7]. The cooperation of Hsp70 and Hsp90 is known to facilitate folding and function of proteins implicated in cell development, such as steroid hormone receptors and kinases [8, 9].

Stress inducible protein 1 (STI1) was first described in mouse [10], and now also known as Hsp70-Hsp90 organising protein (Hop), acts as a module that allows Hsp70 and Hsp90 to interact stably, thereby facilitating substrate transfer from Hsp70 to Hsp90. Interestingly, Hsp70 and Hsp90 resident in the cytosols of E. coli and yeast as well as their homologs localized to mouse ER were shown to interact directly independent of Hop mediation [11, 12, 13, 14]. Although E. coli lacks a Hop homolog [15] and the same protein is not essential in yeast [16], it has been reported to play an important role in the development of Trypanosoma cruzi and Trypanosoma brucei parasites [17]. This shows that the role of Hop varies across species and developmental stages. In light of the essential roles of the P. falciparum cytosol localised chaperones, PfHsp90 and PfHsp70-1, PfHop has been proposed as a potential antimalarial drug target [18, 19] This is partly because it occurs in complex with the two chaperones, and also exhibits some degree of sequence divergence from the human homolog, thus raising prospects for selective targeting by small molecule inhibitors [18]. Indeed, in some disease models such as cancer [20] and leishmaniasis [21, 22], the essential role of Hop has made it a promising drug target.

Hop is a conserved and stress inducible protein that possesses three tetratricopeptide repeats (TPR): TPR1, TPR2A and TPR2B [10]. Both Hsp70 and Hsp90 interact with Hop via the C-terminal EEVD motif, present in the two molecular chaperones [19, 23]. Hop interacts with Hsp70 and Hsp90 via its TPR1 and TPR2A domains, respectively [23]. While for a long time the role of the TPR2B domain of Hop has remained largely elusive, it is now thought that Hsp70 first binds to the TPR1 domain of Hop before switching to the TPR2B domain to facilitate substrate transfer to Hsp90 [20, 23].

In light of the importance of both PfHsp70-1 and PfHsp90 in the survival of the malaria parasite, there has been growing interest in identifying inhibitors targeting the function of these two molecular chaperones. Compounds that inhibit PfHsp70-1 [24, 25, 26] and PfHsp90 [9, 27] have been identified, and some of them exhibit antiplasmodial activity. Some compounds that target PfHsp90 function reverse parasite resistance to traditional antimalarial drugs, such as chloroquine (reviewed in [28]). We previously described Plasmodium falciparum Hop (PfHop), which co-localises and associates with both PfHsp70-1 and PfHsp90 [18, 19]. While Hop in other organisms, such as yeast and human, has been rather extensively characterised, the structure and function of PfHop remain to be elucidated.

Here, we show that PfHop is a monomeric, elongated but folded protein, which loses most of its secondary structure at temperatures above 40 ºC. We discuss the implications of our findings with respect to the role of PfHop in coordinating the Hsp70-Hsp90 pathway in P. falciparum.

2. Methods and materials

2.1 Materials

Reagents used in this study, unless otherwise stated, were purchased from Merck Chemicals (Darmstadt, Germany), Thermo Scientific (Illinois, USA), Zymo Research (USA), Melford (Suffolk, UK), and Sigma-Aldrich (USA). Nickel NTA resin was purchased from Thermo Scientific (USA). ECL was purchased from (ThermoFisher Scientific, USA). The expression and purification of his-tagged recombinant forms of PfHop was confirmed by Western blotting using anti-His antibodies (Thermo Scientific, USA). Furthermore, rabbit raised anti-PfHop antibodies (Eurogentec, Belgium; [18]) were also used to confirm the presence of recombinant PfHop protein.

2.2 Expression and purification of recombinant PfHop

Recombinant PfHop (PF3D7_1434300) was overexpressed in Escherichia coli XL1 Blue cells and purified by nickel affinity chromatography as previously described [18, 19]. The Ni-affinity purified proteins were extensively dialysed in SnakeSkin dialysis tubing 10 000 MWCO (ThermoFisher Scientific, USA) against buffer A [20 mM Tris-HCl, pH 7.5, 10 mM NaCl, 5% (v/v) glycerol, 0.2 mM Tris-carboxyethyl phosphine (TCEP)]. The protein from Ni-NTA chromatography was used to perform conventional CD spectroscopy and tryptophan fluorescence assays. SRCD and SAXS analyses were performed using protein that was further purified using ion exchange and size exclusion chromatography as follows. The dialysed protein was further purified using anion exchange chromatography using a Tricorn MonoQ 4.6/100 PE column (G.E Healthcare LS, USA). PfHop was eluted by applying buffer B (20 mM Tris-HCl, pH 7.5, 10 mM NaCl, 0.2 mM TCEP) to the column using a linear (0.1–1.0 M) NaCl gradient. As the final purification step and to evaluate the oligomeric state of PfHop, size exclusion chromatography was used. Following anion exchange, fractions containing pure PfHop were pooled together and loaded onto a HiLoad 16/600 SuperdexTM 200 pg column equilibrated with buffer C (10 mM Tris-HCl, pH 8, 300 mM NaCl containing 5% glycerol, 0.2 mM TCEP). Eluted fractions were analysed using SDS-PAGE to determine the purity and homogeneity of the PfHop protein. Authenticity of the purified protein was confirmed by sequencing using MALDI-TOF mass spectrometry at the Biocenter Oulu Proteomics Core Facility, Oulu University, Finland. The protein concentration was determined by measuring the UV absorbance at 280 nm using a Nanodrop ND100 (ThermoFisher Scientific, USA).

The molecular weight of PfHop was determined using multi-angle static light scattering (MALS) coupled to size exclusion chromatography using a Superdex S200 Increase 10/300 GL column (GE Healthcare). The column, equilibrated with buffer C, was coupled to a mini DAWN TREOS MALS detector (Wyatt Technology, Germany) and an ERC RefraMAx520 differential refractometer (ERC, Germany). 100 μg of PfHop in buffer C was injected into the column using a flow rate of 0.5 ml/min. BSA and ovalbumin were used as molecular-weight controls. The molecular weight of PfHop was determined based on the measured light scattering at three different angles and the refractive index using the ASTRA software version 6.1.5.22 (Wyatt Technology, Germany).

2.3 Investigation of the secondary structure of PfHop

The secondary structure of PfHop was investigated using synchrotron radiation (SR) and conventional circular dichroism (CD) spectroscopy. The spectral measurements were conducted at the UV-CD12 beam line (Anka, Karlsruhe) under temperature-controlled conditions. PfHop at a concentration of 0.5 mg/ml dialysed in buffer D (10 mM K3PO4, pH 7.0, 150 NaF) was analysed using a 98.56 μm path length round cell cuvette (Suprasil, Hellma Analytics, Germany) at a constant temperature of 10°C. A total of 3 full spectral scans were recorded from 280 to 175 nm and averaged. CD spectroscopy experiments were done using a Jasco J-1500 CD spectrometer (JASCO, Tokyo, Japan) and Chirascan CD Spectrometer (Applied Photophysics, UK) with a temperature-controlled Peltier. Recombinant proteins at a final concentration of 2 μM were analysed using a 2-mm path-length quartz cuvette (Hellma). Spectral scans were recorded from 250 to 180 nm and averaged for least 3 scans. The SRCD data were processed and deconvoluted using the Dichroweb server [29] and the CONTINLL algorithm with the SP175 reference set [30]. To further predict the secondary structure content of PfHop, the BeStSel server (http://bestsel.elte.hu/; [31, 32]) and the Phyre2 server (http://sbg.bio.ic.ac.uk/phyre2/; [33]) were also used. In order to investigate the heat stability of PfHop, the protein was subjected to increasing temperature (10°C to 90°C using 5°C intervals for SRCD and 20 to 90°C for CD) and full spectra recorded when the temperature was raised from 20°C—90°C. Similarly, spectra were recorded upon subjecting the protein to a downward shift in temperature from 90°C to 20°C. Melting curves were plotted by monitoring the CD signal at 192, 210 and 220 nm using the Jasco J-1500 CD spectrometer and further validated using Chirascan CD spectrometer (Applied Photophysics, UK). The CD spectral measurements were expressed as ratio of signal recorded at a particular temperature compared to the SRCD signal recorded at 10°C. This facilitated estimation of the folded protein fraction of the protein at the respective temperature as previously described [34, 35]. The tertiary structure of the protein was probed in the presence of varying concentrations of denaturants, urea (0–8 M) and guanidine hydrochloride (0–6 M).

Fluorescence spectra were recorded following initial excitation at 295 nm and emission was determined at wavelength range of 300 nm to 400 nm using JASCO FP-6300 spectrofluorometer (JASCO, Tokyo, Japan).

2.4 Small-angle X-ray scattering analysis for PfHop shape determination

Synchrotron small-angle X-ray scattering (SAXS) data were collected on the EMBL Hamburg Outstation beam line P12 at PETRA III/DESY (Hamburg). PfHop (2.2 mg/ml) and buffer samples were exposed to X-rays with a wavelength of 1.240 Å for 0.045 s. Pre-processed data were further analysed with the ATSAS software package [36]. The distance distribution calculation and ab initio modelling were performed using GNOM [37] and the GASBOR package [38], respectively. Human Hop TPR1 (1ELW; [39]) and bakers’s yeast TPR2AB domains (3QU3; [23]) were manually fitted in the ab initio envelope using PyMOL 2.3.2 (Schrödinger, USA). An Rg value of 5.3 nm was determined visually from the linear part of the low scattering angles (0.0087–0.0715 nm-1) using PRIMUS [40]. The Dmax for PfHop was estimated as 24 nm, also using PRIMUS.

3. Results

3.1 Oligomeric state of recombinant PfHop

Recombinant PfHop was purified using nickel affinity chromatography as previously described [18]. The protein was further purified using ion exchange and subsequently subjected to size exclusion chromatography (S1 Fig).

Hop has been reported to exist as either monomer [21, 41, 42] or dimer [43, 44], andas largely monomeric, forming weak dimers [45]. Based on size exclusion chromatography, PfHop eluted as an elongated monomer under reducing conditions. A small fraction of dimer, likely due to partial oxidation, could be seen in some batches (S1C Fig, lanes 1–5). A recent study [46] reported that PfHop exists as a dimer. However, using multi-angle light scattering coupled to size exclusion chromatography we observed that PfHop occurs as a monomer of 73 kDa (Fig 1). This is 8% larger than the calculated theoretical molecular weight 67.6 kDa. A previous independent study [20] similarly reported an apparently higher molecular weight for STI1 that was determined using gel filtration. As a control, we determined molecular weights for bovine serum albumin (73 kDa) and ovalbumin (45 kDa), which were 10% and 6%, respectively, larger than their calculated theoretical molecular weights.

Fig 1. Determination of the oligomeric status of PfHop.

Fig 1

Size exclusion chromatography of PfHop displays a single peak. The molecular weight of the peak calculated using static light scattering, shown as a black line, represents a PfHop monomer.

3.2 Analysis of the secondary structure of PfHop

To confirm the folding state and secondary structure composition of recombinant PfHop, synchrotron radiation circular dichroism (SRCD) spectroscopy was conducted. SRCD spectra were recorded between 175 and 280 nm at 10°C. The PfHop spectra exhibited 2 negative minima around 222 and 208 nm and a positive peak at 194 nm (Fig 2A), characteristic of a predominantly α-helical protein [47] as previously reported [46]. Deconvolution of the spectra with Dichroweb indicated a predominantly α-helical structure comprising 77% α-helices (Table 1). This was supported by predictions from BeStSel and Phyre2 (S1 Table). The helical content estimated here for PfHop is comparable to that for Leishmania braziliensis Hop (LbHop) which was reported to be around 75% [42]. Notably, the PfHop helical content of 77% we observed here is much higher than that the 57% obtained for the same protein in a recent independent study [46]. While, it is not clear why such a wide discrepancy has been reported for PfHop helical content, our findings reconcile with that reported for its close homolog, LbHop [42]. Overall, the predominantly α-helical structure of PfHop is consistent with the predicted three-dimensional model of PfHop which showed that all its three TPR motifs are α-helical in nature [18]. Furthermore, based on the previously generated three-dimensional model of PfHop, residues of PfHop that are implicated in making direct contact with PfHsp70-1/PfHsp90 are positioned within the grooves of the α-helical TPR domains [18].

Fig 2. Secondary structure analysis of PfHop.

Fig 2

(A) SRCD spectrum of full-length PfHop. SRCD spectral scans monitoring denaturation of PfHop upon exposure to increasing heat stress (10°C to 90°C). (B) Shown is the CD spectrum of PfHop monitored at 222 nm upon thermal denaturation by upscaling temperature from 20°C to 90°C. Similarly, the CD spectrum for the renaturation attempt of PfHop upon temperature downscale from 90°C to 20°C is illustrated. The thermal transitions (Tm1 and Tm2) are shown. (C) The folded fraction of PfHop as a function of temperature was monitored using CD signals at 192, 210 and 220 nm. (D) Urea-induced unfolding of PfHop is shown. (E) Represents the fluorescence emission spectra of PfHop monitored at 300–450 nm after an initial excitation at 295 nm. The recombinant PfHop protein tryptophan fluorescence emission spectra were recorded under various GdHCl and urea concentrations. Notable, is the red spectral shift obtained for of PfHop exposed to various GdHCl and urea concentrations.

Table 1. SAXS parameters for PfHop.

Sample Rg (nm) Dmax (Å) MW (kDa) Expected MW (kDa)
SLS 73 67.6
SAXS 5.3 240 67.6

PfHop mediates interaction between PfHsp70-1 and PfHsp90 [18, 20], and its expression is heat-induced [18]. The roles of these two chaperones become particularly important when the parasite is subjected to physiological stress, such as during clinical malaria fever episodes [48]. It is therefore important that heat shock proteins of parasite origin exhibit resilience to heat stress conditions. PfHsp70-1 is stable at high temperatures and is most active at 48 ºC—50 ºC and is known to retain its ATPase activity at up to 80 ºC [6; 34]. However, it remains to be established whether PfHop exhibits the same resilience to heat stress. To probe this, we investigated the heat stability of recombinant PfHop in vitro. As a control, the denaturation of PfHop exposed to urea (0–8 M) was also monitored using CD (Fig 2C). Next, we monitored the folded fraction of PfHop in response to exposure to increased temperature conditions using SRCD (10°C to 90°C) (Fig 2A) and CD spectrometry (assay was conducted at 20°C—90°C; Fig 2B). PfHop appeared stable at temperatures lower than 40°C. However, at higher temperatures the protein lost its fold, and only 50% of the protein retained its folded state at 45°C (Fig 2C). Notably, the spectra suggest that the protein simultaneously loses both its α-helical and β-compositions in response to heat stress through two unfolding transitions (Tm1 and Tm2) (Fig 2B). CD spectrometry was used to monitor heat-induced denaturation of PfHop at a temperature range of 20°C—90°C (Fig 2B). The double phased unfolding transitions we observed here closely mirror those reported for PfHop in an independent study [46]. An attempt to refold the heat-denatured PfHop by lowering temperature from 90°C—20°C showed that the protein subjected to temperatures above 70°C could not refold. Our findings suggest that PfHop is less stable to heat stress than PfHsp70-1, whose ATPase activity was found to be optimal around 50°C [34]. In addition, PfHsp70-1 exhibits chaperone activity (suppressing heat induced aggregation of protein) at 48°C [6].

Furthermore, tryptophan fluorescence spectroscopy was conducted to monitor the tertiary structural organisation of PfHop in the presence of varying amounts of urea and guanidine hydrochloride (GdHCl). A red shift was observed with maximum peaks at 350 nm (associated with 6 M GdHCl) and 343 nm (associated with 8 M urea) (Fig 2E). PfHop was more sensitive to GdHCl, which is a stronger denaturant. This is in agreement to a previous observation for PfHsp70-1 protein [34].

3.3 Low-resolution structure of PfHop in solution

In order to gain further insight into the structure of PfHop, we determined its low-resolution structure in solution using SAXS (Fig 3). The X-ray scattering curve (Fig 3A), the Kratky plot (Fig 3B), and the distance distribution function (Fig 3C) together indicate that PfHop is an elongated protein with a maximum dimension of approximately 24 nm (Table 1). PfHop consists mostly of folded parts connected by flexible linkers. Thus, as expected, the TPR domains likely are arranged like pearls on a string. The distance distribution function (Fig 3C) indicates at least two stable domains with maxima at ~3 and ~5 nm within the Dmax of 240 Å. The Dmax obtained for PfHop falls within the range obtained for other Hop homologues; 180 Å for LbHop [42], 193 Å for Hop [43], 230 Å for PfHop [46] and 260 Å for STI1 [20]. Altogether, these values confirm Hop to generally assume an extended conformation across species. An ab initio dummy residue model calculated using GASBOR (Fig 3D) is consistent with the above data and shows an excellent fit to the experimental data (Fig 3) with a χ2 value of 1.06. The model consists of an elongated shape with some more compact regions, as observed for STI1 [20]. This model visually fits perfectly to crystal structures of human and yeast Hop TPR1 (1ELW, [39]) as well as that of the TPR2AB (3UQ3, [23]) domain (Fig 3D).

Fig 3. SAXS analysis of PfHop.

Fig 3

(A) Fit of a calculated SAXS curve based on an ab initio model (red line) on the experimental SAXS curve (grey dots) measured for PfHop. (B) Kratky plot derived from the scattering data. (C) Distance distribution function. (D) An Ab initio model of PfHop (green), determined using GASBOR compared with crystal structures of human Hop TPR2AB (3UQ3) and baker’s yeast TPR1 domains (1ELW) (cyan). The lower panel is related to the upper one, by a 90° clockwise rotation along the plane of view.

4. Discussion

PfHop is thought to facilitate the functional cooperation between PfHsp70-1 and PfHsp90, both prominent cytosolic molecular chaperones of P. falciparum [18, 19]. The Hsp70-Hop-Hsp90 pathway plays an important role in cellular development, as it facilitates folding and maturation of proteins, such as kinases and steroid hormone receptors [49]. Inhibition of both PfHsp90 and PfHsp70-1 leads to parasite death [7, 24, 26], making these molecular chaperones potential antimalarial drug targets. In the current study, we demonstrated that PfHop is unstable at temperatures above 40°C. Furthermore, the protein is denatured at elevated temperatures through two distinct unfolding transitions (Fig 2), in agreement with a recent independent study [46]. The two unfolding transitions are consistent with a protein possessing domains of varied conformational stability. This is consistent with the multi-domain nature of PfHop as observed in the current study. In agreement with this, the N-terminus of Hop is reportedly flexible while its C-terminus is deemed to be compact [20].

We previously observed that PfHop, PfHsp70-1, and PfHsp90 occur in a complex, and that PfHop directly associates with the EEVD domains of PfHsp70-1 and PfHsp90 [18, 19]. This suggests that PfHop modulates functional cooperation between PfHsp70-1 and PfHsp90. The development of clinical malaria is associated with body temperature rising to 41.6°C. At such high temperatures, the role of heat shock proteins in maintaining proteostasis becomes unquestionably important, as is evidenced by the elevated expression of key molecular chaperones, such as PfHsp70-1 and PfHsp90 [7, 50]. It is intriguing to imagine how PfHsp70-1 and PfHsp90 cooperate in the presence of limiting levels of PfHop, as occurs during sustained heat stress conditions induced by malaria fever. It is possible that under extended stress conditions, the role of Hop becomes less vital and that perhaps Hsp70 and Hsp90 may directly interact. Indeed, a study showed that despite lack of Hop in E. coli, Hsp70 and Hsp90 from E. coli are capable of direct interaction [15]. In addition, Hsp70 and Hsp90 chaperones resident in yeast cytosol and mouse ER were reported to directly bind without Hop as an adaptor [13, 14]. In a previous study, we observed complexes of PfHsp70-1 and PfHsp90 in which PfHop was present based on size exclusion chromatography of parasite lysates [18]. However, we also observed eluates representing a complex of PfHsp70-1 and PfHsp90, in which PfHop was absent [18]. A non-canonical Hop homologue from Caenorhabditis elegans lacks the TPR1 domain, hence it is thought to be biased towards binding to Hsp90 than Hsp70 [51]. Altogether, our findings and those of others suggest that the function of Hop may vary across species and may also depend on the prevailing cellular physiological conditions.

Findings on the oligomeric status of Hop have remained controversial as independent studies have reported it to be either monomeric [41] or dimeric [44], or largely monomeric but forming also weak dimers [45]. In the current study, we sought to establish the oligomeric status of PfHop. Based on size-exclusion chromatography and multi-angle static light scattering, we conclude that PfHop occurs as a monodisperse monomer (Fig 1). This conflicts with a recent study which reported PfHop to exist as a dimer [46]. It is important to note that we also observed a dimeric fraction which we think is on account of unspecific disulphide bridge formation that occurs under non-reducing conditions. Interestingly, our previous findings using SPR showed that PfHop self-associates with higher affinities [19], suggesting that PfHop may form oligomers. It is possible that PfHop self-association occurs transiently, hence may be detected by techniques such as SPR but not by other techniques such as SEC. This could account for the conflicting findings. On the other hand, human Hop has been reported to form dimers [44, 52, 53], but it remains to be confirmed whether these are of functional significance. In addition, Hop has also been suggested to form elongated monomers, which are difficult to resolve using gel filtration [41]. Indeed, the low-resolution solution structure determined by SAXS shows that PfHop is a highly elongated and multidomain protein. This agrees with several previous independent studies [20, 42, 43, 46]. Notably, we observed that the folded domains of PfHop are organised like beads on a string. This is consistent with the predicted concave nature of its predominantly α-helical TPR motifs [18]. TPR motifs of human Hop have been described to occur as grooves into which the C-terminal EEVD motifs of Hsp90 and Hsp70 bind in extended form [39]. Our PfHop SAXS data is consistent with this proposed model.

Altogether, our findings established that PfHop is an elongated, predominantly α-helical, monomeric, protein. Its heat stability is lower than that reported for PfHsp70-1, suggesting that its function may be compromised at high temperatures associated with clinical malaria progression.

Supporting information

S1 Fig. Purification of PfHop by ion exchange and size exclusion chromatography.

(A) SDS-PAGE analysis of the five samples collected from the main peak (lanes 1–5). Ion exchange chromatography of PfHop purification was monitored at 280 nm. Protein that bound to the column was then eluted under NaCl gradient. The five fractions obtained were pooled together for subsequent SEC analysis. (B) SDS-PAGE analysis of several fractions (lanes 1–11) of PfHop obtained by SEC are shown. (C) SDS-PAGE analysis of several fractions (lanes 1–12) of PfHop obtained by SEC are shown.

(DOCX)

S2 Fig. Mass spectrometry sequencing data for PfHop.

(DOCX)

S1 Table. PfHop secondary structure content.

(DOCX)

S1 Raw Images

(PDF)

Acknowledgments

We thank Drs. Arne Raasakka, Erik Hallin, and Juha Kallio for SRCD and SAXS data collection as well as help with data processing. We acknowledge the KIT light source for provision of instruments at the beamline UV-CD12 of the Institute of Biological Interfaces (IBG2), and we would like to thank the Institute for Beam Physics and technology (IBPT) for the operation and storage ring, the Karlsruhe Research Accelerator (KARA). We would like to acknowledge the Biophysics, Structural Biology, and Screening (BiSS) facilities at University of Bergen for access to the static light scattering instrument. We are grateful to the office of University of Stellenbosch Central Analytical Facilities for allowing us access to use their Chirascan CD Spectrometer.

Data Availability

All relevant data are within the manuscript and its Supporting Information files.

Funding Statement

1. IK, Sigrid Jusélius Foundation; https://sigridjuselius.fi/en/ 2. AS, L1/402/14–1; Deutsche Forchungsgemeinshaft; https://www.validate-network.org/event/german-african-cooperation-projects-in-infectiology-dfg 3. AS; 75464; 92598; National Research Foundation/Department of Science & Innovation of South Africa; https://www.nrf.ac.za/ 3. TZ; 111989; National Research Foundation of South Africa; www.nrf.ac.za

References

  • 1.Bukau B, Weissman J, Horwich A. Molecular chaperones and protein quality control. Cell. 2006, 125: 443–451. 10.1016/j.cell.2006.04.014 [DOI] [PubMed] [Google Scholar]
  • 2.Shonhai A. Role of Hsp70s in development and pathogenicity of Plasmodium species: In: Heat Shock Proteins of Malaria; Shonhai A., Blatch G., Ed.; Springer: New York, NY, USA, 2014, pp 47–70. [Google Scholar]
  • 3.Charnaud SC, Dixon MWA, Nie CQ, Chappell L, Sanders PR, Nebl T, et al. The exported chaperone Hsp70-x supports virulence functions for Plasmodium falciparum blood stage parasites. PLoS ONE. 2017, 12: e0181656 10.1371/journal.pone.0181656 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Zininga T, Ramatsui L, Shonhai A. Heat shock proteins as immunomodulants. Molecules. 2018, 23: 2846. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Shonhai A, Boshoff A, Blatch G L. Plasmodium falciparum heat shock protein 70 is able to suppress the thermosensitivity of an Escherichia coli DnaK mutant strain. Mol. Genet. Genomics. 2005, 274: 70–78. 10.1007/s00438-005-1150-9 [DOI] [PubMed] [Google Scholar]
  • 6.Shonhai A, Botha M, de Beer TAP, Boshoff A, Blatch GL. Structure-function study of Plasmodium falciparum Hsp70 using three-dimensional modelling and in-vitro analyses. Protein. Pept. Lett. 2008, 15: 1117–1125. 10.2174/092986608786071067 [DOI] [PubMed] [Google Scholar]
  • 7.Banumathy G, Singh V, Pavithra SR, Tatu U. Heat shock protein 90 is essential for Plasmodium falciparum growth in human erythrocytes. J. Biol. Chem. 2003, 278: 18336–18345. 10.1074/jbc.M211309200 [DOI] [PubMed] [Google Scholar]
  • 8.Taipale M, Jarosz DF, Lindquist S. HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat. Rev. Mol. Cell. Biol. 2010, 11: 515–28. 10.1038/nrm2918 [DOI] [PubMed] [Google Scholar]
  • 9.Posfai D, Eubanks AL, Keim AI, Lu KY, Wang GZ, Hughes PF, et al. Identification of Hsp90 inhibitors with anti-Plasmodium activity. Antimicrob. Agents. Chemother. 2018, 62: e01799–17. 10.1128/AAC.01799-17 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Lässle M, Blatch GL, Kundra V, Takatori T, Zetter BR. Stress inducible, murine protein mSTI1. J. Biol. Chem. 1997, 272: 1876–1884. 10.1074/jbc.272.3.1876 [DOI] [PubMed] [Google Scholar]
  • 11.Yamamoto S, Subedi GP, Hanashima S, Satoh T, Otaka M, Wakui H, et al. ATPase activity and ATP-dependent conformational change in the co-chaperone HSP70/HSP90-organizing protein (HOP). J Biol Chem. 2014, 289: 9880–9886. 10.1074/jbc.M114.553255 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Kravats AN, Doyle SM, Hoskins JR, Genest O, Doody E, Wickner S. Interaction of E. coli Hsp90 with DnaK involves the DnaJ binding region of DnaK. J Mol Biol. 2017, 429: 858–872. 10.1016/j.jmb.2016.12.014 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Kravats AN, Hoskins JR, Reidy M, Johnson JL, Doyle SM, Genest O, et al. Functional and physical interaction between yeast Hsp90 and Hsp70. Proc. Natl. Acad. Sci. U S A. 2018, 115: 2210–2219. 10.1073/pnas.1719627115 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Sun M, Kotler JL, Liu S, Street TO. The endoplasmic reticulum (ER) chaperones BiP and Grp94 selectively associate when BiP is in the ADP conformation. J Biol Chem. 2019, 294: 6387–96. 10.1074/jbc.RA118.007050 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Genest O, Hoskins JR, Kravats AN, Doyle SM, Wickner S. Hsp70 and Hsp90 of E. coli directly interact for collaboration in protein remodeling. J. Mol. Biol. 2015, 427: 3877–3889. 10.1016/j.jmb.2015.10.010 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Reidy M, Kumar S, Anderson DE, Masison DC. Dual roles for yeast Sti1/Hop in regulating the Hsp90 chaperone cycle. Genetics. 2018, 209: 1139–1154. 10.1534/genetics.118.301178 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Schmidt JC, Manhães L, Fragoso SP, Pavoni DP, Krieger MA. Involvement of STI1 protein in the differentiation process of Trypanosoma cruzi. Parasitol Int. 2018, 67:131–139. 10.1016/j.parint.2017.10.009 [DOI] [PubMed] [Google Scholar]
  • 18.Gitau GW, Mandal P, Blatch GL, Przyborski J, Shonhai A. Characterization of the Plasmodium falciparum Hsp70-Hsp90 organising protein (PfHop). Cell Stress Chaperone. 2012, 17: 191–202. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Zininga T, Makumire S, Gitau GW, Njunge JM, Pooe OJ, Klimek H, et al. Plasmodium falciparum Hop (PfHop) interacts with the Hsp70 chaperone in a nucleotide-dependent fashion and exhibits ligand selectivity. PLoS ONE. 2015, 10: e0135326 10.1371/journal.pone.0135326 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Röhl A, Wengler D, Madl T, Lagleder S, Tippel F, Herrmann M, et al. Hsp90 regulates the dynamics of its cochaperone Sti1 and the transfer of Hsp70 between modules. Nat. Commun. 2015, 6: 6655 10.1038/ncomms7655 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Morales MA, Watanabe R, Dacher M, Chafey P, y Fortéa JO, Scott DA, et al. Phosphoproteome dynamics reveal heat-shock protein complexes specific to the Leishmania donovani infectious stage. Proc Natl Acad Sci. 2010, 107: 8381–8386. 10.1073/pnas.0914768107 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Hombach A, Clos J. No stress–Hsp90 and signal transduction in Leishmania. Parasitology. 2014, 141:1156–66. 10.1017/S0031182013002151 [DOI] [PubMed] [Google Scholar]
  • 23.Schmid AB, Lagleder S, Gräwert MA, Röhl A, Hagn F, Wandinger SK, et al. The architecture of functional modules in the Hsp90 co-chaperone Sti1/Hop. EMBO J. 2012, 31: 1506–1517. 10.1038/emboj.2011.472 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Cockburn IL, Boshoff A, Pesce ER, Blatch GL. Selective modulation of plasmodial Hsp70s by small molecules with antimalarial activity. Biol. Chem. 2014, 395: 1353–1362. 10.1515/hsz-2014-0138 [DOI] [PubMed] [Google Scholar]
  • 25.Zininga T, Pooe OJ, Makhado PB, Ramatsui L, Prinsloo E, Achilonu I, et al. Polymyxin B inhibits the chaperone activity of Plasmodium falciparum Hsp70. Cell Stress Chaperones. 2017, 22: 707–715. 10.1007/s12192-017-0797-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Zininga T, Ramatsui L, Makhado PB, Makumire S, Achilinou I, Hoppe H, et al. (−)-Epigallocatechin-3-gallate inhibits the chaperone activity of Plasmodium falciparum Hsp70 chaperones and abrogates their association with functional partners. Molecules. 2017, 22: 2139. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Wang T, Bisson WH, Maser P, Scapozza L, Picard D. Differences in conformational dynamics between Plasmodium falciparum and human Hsp90 Orthologues enable the structure based discovery of pathogen-selective inhibitors. J. Med. Chem. 2014, 57: 2524–2535. 10.1021/jm401801t [DOI] [PubMed] [Google Scholar]
  • 28.Shahinas D, Folefoc A, Pillai D. Targeting Plasmodium falciparum Hsp90: towards reversing antimalarial resistance. Pathogens. 2013, 2: 33–54. 10.3390/pathogens2010033 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Lobley A, Whitmore L, Wallace BA. DICHROWEB: an interactive website for the analysis of protein secondary structure from circular dichroism spectra. Bioinformatics. 2002, 18: 211–212. 10.1093/bioinformatics/18.1.211 [DOI] [PubMed] [Google Scholar]
  • 30.Compton LA, Johnson WC Jr. Analysis of protein circular dichroism spectra for secondary structure using a simple matrix multiplication. Anal. Biochem. 1986, 155: 155–167. 10.1016/0003-2697(86)90241-1 [DOI] [PubMed] [Google Scholar]
  • 31.Micsonai A, Wien F, Kernya L, Lee YH, Goto Y Réfrégiers M, et al. Accurate secondary structure prediction and fold recognition for circular dichroism spectroscopy. Proc. Natl. Acad. Sci. U S A. 2015, 112: 3095–3103. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Micsonai A, Wien F, Bulyáki É, Kun J, Moussong É, Lee YH, et al. BeStSel: a web server for accurate protein secondary structure prediction and fold recognition from the circular dichroism spectra. Nucleic Acids Res. 2018, 46: 315–322. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Kelley LA, Mezulis S, Yates CM, Wass MN, Sternberg MJ. The Phyre2 web portal for protein modeling, prediction and analysis. Nat. Protoc. 2015, 10: 845–58. 10.1038/nprot.2015.053 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Misra G, Ramachandran R. Hsp70-1 from Plasmodium falciparum: protein stability, domain analysis and chaperone activity. Biophys. Chem. 2009, 142: 55–64. 10.1016/j.bpc.2009.03.006 [DOI] [PubMed] [Google Scholar]
  • 35.Zininga T, Achilonu I, Hoppe H, Prinsloo E, Dirr HW, Shonhai A. Overexpression, purification and characterization of the Plasmodium falciparum Hsp70-z (PfHsp70-z). PLoS ONE. 2015, 10: e0129445 10.1371/journal.pone.0129445 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Franke D, Petoukhov MV, Konarev PV, Panjkovich A, Tuukkanen A, Mertens et al. ATSAS 2.8: a comprehensive data analysis suite for small-angle scattering from macromolecular solutions. J. Appl. Cryst. 2017, 50: 1212–1225. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Svergun DI. Determination of the regularization parameter in indirect-transform methods using perceptual criteria. J. Appl. Crystallogr. 1992, 25: 495–503 [Google Scholar]
  • 38.Svergun DI Petoukhov MV, Koch MHJ. Determination of domain structure of proteins from X-ray solution scattering. Biophys. J. 2001, 80: 2946–2953. 10.1016/S0006-3495(01)76260-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Scheufler C, Brinker A, Bourenkov G, Pegoraro S, Moroder L, Bartunik H, et al. Structure of TPR domain–peptide complexes: critical elements in the assembly of the Hsp70–Hsp90 multichaperone machine. Cell. 2000, 101: 199–210. 10.1016/S0092-8674(00)80830-2 [DOI] [PubMed] [Google Scholar]
  • 40.Konarev PV, Volkov VV, Sokolova AV, Koch MHJ, Svergun DI. PRIMUS—a Windows-PC based system for small-angle scattering data analysis. J. Appl. Cryst. 2003, 36: 1277–1282. [Google Scholar]
  • 41.Yi F, Doudevski I, Regan L. HOP is a monomer: Investigation of the oligomeric state of the co‐chaperone HOP. Protein Sci. 2010, 19: 19–25. 10.1002/pro.278 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Batista FA, Seraphim TV, Santos CA, Gonzaga MR, Barbosa LR, Ramos CH, et al. Low sequence identity but high structural and functional conservation: The case of Hsp70/Hsp90 organizing protein (Hop/Sti1) of Leishmania braziliensis. Arch Biochem Biophys. 2016, 600: 12–22. 10.1016/j.abb.2016.04.008 [DOI] [PubMed] [Google Scholar]
  • 43.Onuoha SC, Coulstock ET, Grossmann JG, Jackson SE. Structural studies on the co-chaperone Hop and its complexes with Hsp90. J Mol Biol. 2008, 379: 732–44. 10.1016/j.jmb.2008.02.013 [DOI] [PubMed] [Google Scholar]
  • 44.Prodromou C, Siligardi G, O'Brien R, Woolfson DN, Regan L, Panaretou B, Regulation of Hsp90 ATPase activity by tetratricopeptide repeat (TPR)-domain co‐chaperones. EMBO J. 1999, 18: 754–762. 10.1093/emboj/18.3.754 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Southworth DR, Agard DA. Client-loading conformation of the Hsp90 molecular chaperone revealed in the cryo-EM structure of the human Hsp90: Hop complex. Mol. Cell. 2011, 42: 771–781. 10.1016/j.molcel.2011.04.023 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Silva NS, Bertolino-Reis DE, Dores-Silva PR, Anneta FB, Seraphim TV, Barbosa LR, et al. Structural studies of the Hsp70/Hsp90 organizing protein of Plasmodium falciparum and its modulation of Hsp70 and Hsp90 ATPase activities. Biochim Biophys Acta Proteins Proteom. 2020, 1868: 140282 10.1016/j.bbapap.2019.140282 [DOI] [PubMed] [Google Scholar]
  • 47.Sreerama N, Woody RW. Estimation of protein secondary structure from Circular Dichroism spectra: Comparison of CONTIN, SELCON, and CDSSTR methods with an expanded reference set. Anal. Biochem. 2000, 287: 252–260. 10.1006/abio.2000.4880 [DOI] [PubMed] [Google Scholar]
  • 48.Pallavi R, Archarya P, Chandran S, Daily JP, Tatu U. Chaperone expression profiles correlate with distinct physiological states of Plasmodium falciparum in malaria patients. Malar. J. 2010, 9, 236 10.1186/1475-2875-9-236 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Carrigan PE, Riggs DL, Chinkers M, Smith DF. Functional comparison of human and Drosophila Hop reveals novel role in steroid receptor maturation. J. Biol. Chem. 2005, 280: 8906–8911. 10.1074/jbc.M414245200 [DOI] [PubMed] [Google Scholar]
  • 50.Zininga T, Achilonu I, Hoppe H, Prinsloo E, Dirr HW, Shonhai A. Plasmodium falciparum Hsp70-z (Hsp110c) exhibits independent chaperone activity and interacts with Hsp70-1 in a nucleotide dependent fashion. Cell Stress Chaperones. 2016, 21: 499–513. 10.1007/s12192-016-0678-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Gaiser AM, Kaiser CJ, Haslbeck V, Richter K. Downregulation of the Hsp90 system causes defects in muscle cells of Caenorhabditis elegans. PloS ONE. 2011, 6: e25485 10.1371/journal.pone.0025485 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Bose S, Weikl T, Bügl H, Buchner J. Chaperone function of Hsp90-associated proteins. Science. 1996, 274: 1715–1717. 10.1126/science.274.5293.1715 [DOI] [PubMed] [Google Scholar]
  • 53.Hildenbrand ZL, Molugu SK, Herrera N, Ramirez C, Xiao C, Bernal RA. Hsp90 can accommodate the simultaneous binding of the FKBP52 and HOP proteins. Oncotarget. 2011, 2: 43–58. 10.18632/oncotarget.225 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Didier Picard

9 Jan 2020

PONE-D-19-33340

Biophysical analysis of Plasmodium falciparum Hsp70-Hsp90 organizing protein (PfHop) reveals a monomer that is characterised by folded segments connected by flexible linkers

PLOS ONE

Dear Prof. Shonhai,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Your manuscript has now been evaluated by two expert reviewers. Their comments, which partially overlap, need to be addressed in detail. As you'll see, addressing the comments about the thermal stability experiments might also require additional data.

Moreover, previous evidence from the same lab indicating the existence of dimers should not be shrugged of as lightly as it is done in the Discussion on page 12 ("However, a dimeric fraction is observed in non-reducing conditions, indicating unspecific disulphide bridge formation, which would explain some of the previous data [12]"). This needs to be more thoroughly addressed (if necssary also experimentally).

We would appreciate receiving your revised manuscript by Feb 23 2020 11:59PM. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled 'Manuscript'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Didier Picard

Academic Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission’s figures or Supporting Information files. This policy and the journal’s other requirements for blot/gel reporting and figure preparation are described in detail at https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements and https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels.

In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at plosone@plos.org if you have any questions.

3. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

4. Thank you for stating the following in the Acknowledgments Section of your manuscript:

"This study has been funded by the Academy of Finland, the Norwegian Research Council, the Sigrid Jusélius Foundation, a grant (L1/402/14–1) provided to A.S. by the Deutsche Forchungsgemeinshaft (DFG) under the theme, “German–African Cooperation Projects in Infectiology”, the Department of Science and Technology/National Research Foundation (NRF) of South Africa equipment grant (UID, 75464) and NRF mobility grant (UID, 92598) awarded to A.S.; T.Z. is a recipient of the NRF Innovation Post-Doctoral fellowship UID, 111989 and African–German Network of Excellence in Science junior researcher grant."

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

"1. IK, Sigrid Jusélius Foundation; https://sigridjuselius.fi/en/

2. AS, L1/402/14–1; Deutsche Forchungsgemeinshaft ; https://www.validate-network.org/event/german-african-cooperation-projects-in-infectiology-dfg

3. AS; 75464; 92598; National Research Foundation/Department of Science & Innovation of South Africa; https://www.nrf.ac.za/

3. TZ; 111989; National Research Foundation of South Africa; www.nrf.ac.za"

5. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This manuscript from Makumire et al. examines the biophysical properties of the Hsp70/Hsp90 co-chaperone Hop from P. falciparum (PfHop). The main conclusions are:

1) PfHop is primarily monomeric

2) PfHop has folded segments connected by flexible linkers

3) PfHop is unstable at temperatures over 40C

The third conclusion is important because is suggests that PfHop may lose part of its structure/function under fever conditions associated with clinical malaria.

Most of the conclusions are well-supported although I think one control experiment is required. The authors need to establish whether the thermal denaturation is reversible or irreversible. Specifically, an experiment is needed like that shown in Fig2b where the temperature is first increased up to 80C and then decreased back down to 20C. If the denaturation is reversible then these curves should overlap. If it is not reversible then the thermal denaturation results should be interpreted cautiously. I think this is an essential control.

Minor points:

Fig 2A: CD for protein samples is usually reported as molar ellipticity (theta) with units of deg*cm^2/dmol.

Were replicate experiments performed for the thermal melt? If no, then the authors should confirm the reproducibility. Some data on reproducibility should be shown in the text or figures.

The folded fraction (y-axes) in Figures 2B&C is not well-defined because it is not clear whether 80C represent the fully denatured baseline. Also, because it is not whether the folding is cooperative or multi-state it is not clear how to convert the CD signal into a fraction folded value. I would advise plotting the y-axes as the raw CD signal.

SAXS analysis of Hop has been performed in other studies in addition to the Rohl 2015 study (for example Onuoha et al. JMB 2008). It may be helpful to briefly discuss how your SAXS results compares with previous studies.

The discussion cites literature showing Hsp90/Hsp70 directly interacting in the absence of Hop. The ER-specific Hsp70/Hsp90 (BiP/Grp94) also show a direct interaction (see Sun et al. JBC 2019).

Best Regards,

Timothy Street

Reviewer #2: In the manuscript, Makumire and colleagues use a number of biophysical techniques to analyse the Plasmodium falciparum orthologue of the Hsp70/Hsp90 co-chaperone, Hop. The authors produced the protein recombinantly in E.coli as a his-tag fusion and purified it using IMAC and ion exchange chromatography. The purified protein subsequently underwent partial biophysical characterisation using CD/SRCD, SAXS and tryptophan fluorescence. They conclude that PfHop is an elongated monomer comprised mostly of alpha helical secondary structure. In addition, they conclude that PfHop is unstable at temperatures above 40 °C, while its partner protein PfHsp70-1 is stable at much higher temperatures.

Overall the manuscript is straightforward and the data presented are consistent with previous reports, and perhaps not surprising given the sequence similarity and molecular modelling of the PfHop structure, as well as our understanding of the structural and biophysical features of Hop from other organisms. This study provides experimental data to support bioinformatics models and demonstrate that structurally PfHop is similar to Hop from other organisms. A range of appropriate biophysical methods are used in the study, and the experiments appear to have been performed appropriately. Perhaps one limitation is that all of the analyses were conducted with a single concentration of PfHop.

This study is very similar to another one from the Borges lab (doi: 10.1016/j.bbapap.2019.140282.) which has just been published. In this recent paper, the group describes the biophysical characterisation of PfHop, including a number of similar or identical methods to this study (SAXS, tryptophan fluorescence, thermal unfolding and AUC). The fact that this recent paper is so similar should not prevent publication of the current study, but it does provide a good comparison for data generated in two independent labs. The PfHop study is very recent and hence it is possible that this paper may not have been identified prior to submission which is why it is not included. Nevertheless, this study should be an essential comparison to the current manuscript.

The authors have been measured in their interpretation, and in my opinion, could perhaps improve the depth of comparison of their data to other key reports on biophysical characterisation of Hop orthologues without over-stating conclusions. The recent reports on direct interactions between Hsp70 and Hsp90 in eukaryotes needs to be given more priority and included in the introduction, not only the discussion. These studies redefine our understanding of the role that Hop plays in the Hsp70-Hsp90 complex. It is clear Hop is no longer essential for interaction in eukaryotes, although this does not mean it is not required under specific conditions. Therefore, it is not necessarily completely unexpected or surprising that PfHsp70 and PfHsp90 may be able to directly interact in the absence of PfHop.

PfHop is proposed to be instable at temperatures above 40 °C, which has implications for the PfHsp70-PfHsp90 chaperone complex during fever in malaria (where temperatures can reach this temperature). However, the conclusion of instability above 40 °C on the data presented is subjective at best. The authors should calculate the Tm which would give a more direct and comparable temperature stability. In addition, the current discussion fails to explicitly compare this with that reported for human Hop (in the region of 52 degrees C) as indicated by the study from the Regan group. This is important since the implication is that human Hop may be more stable than PfHop, which could imply biochemical differences between the two chaperone systems despite high sequence and structural similarity. In addition, the stability studies have been conducted in vitro and one needs to be cautious in directly extrapolating findings to an in vivo scenario where the protein may behave differently due to the environment. While I think the conclusion can be made, this aspect is not highlighted at all in the manuscript.

What is the relevance of the data shown in Fig 2D? How this relates to the rest of the analysis was not clearly articulated to me.

It may be better to include Fig 3D as its own figure so that it can be made larger.

The SAXS results need to be compared to the studies from the Jackson lab (Onuoha etal J Mol Biol. 2008 Jun 13; 379(4):732-44), who did SAXS on human Hop-Hsp90 complexes and is currently not referenced in the manuscript, and from the Borges lab who have done this (and other biophysical characterisation) on both LmHop (doi: 10.1016/j.abb.2016.04.008.) and PfHop.

How confident are the authors of the SEC-MAL data which appeared to consistently over-estimate the molecular weight of proteins studied? There are other studies on BSA at least which give a molecular weight at 64 kDa?

There are some minor missing articles and inconsistencies e.g. Tpr vs TPR in the manuscript that can be easily corrected with appropriate proofreading.

A minor final point, the abstract makes reference to ‘select number of cellular proteins required for cyto-protection……’. To the best of my knowledge (and I could of course be wrong), there has been limited characterisation of bona fide chaperone clients in malaria and hence, while this statement is likely true, has it been experimentally verified?

The authors are encouraged to deposit the SAXS data in the SASBDB and link the accession number to the manuscript.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Timothy Street

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2020 Apr 28;15(4):e0226657. doi: 10.1371/journal.pone.0226657.r002

Author response to Decision Letter 0


27 Mar 2020

Reviewer #1: This manuscript from Makumire et al. examines the biophysical properties of the Hsp70/Hsp90 co-chaperone Hop from P. falciparum (PfHop). The main conclusions are:

1) PfHop is primarily monomeric

2) PfHop has folded segments connected by flexible linkers

3) PfHop is unstable at temperatures over 40C

The third conclusion is important because is suggests that PfHop may lose part of its structure/function under fever conditions associated with clinical malaria.

Most of the conclusions are well-supported although I think one control experiment is required. The authors need to establish whether the thermal denaturation is reversible or irreversible. Specifically, an experiment is needed like that shown in Fig2b where the temperature is first increased up to 80C and then decreased back down to 20C. If the denaturation is reversible then these curves should overlap. If it is not reversible then the thermal denaturation results should be interpreted cautiously. I think this is an essential control.

Authors Response:

We appreciate the reviewer’s comment and we have repeated the thermal denaturation and included the data for renaturation in Fig 2b as recommended. Indeed, there is no overlap between the two curves suggesting that exposure of the PfHop to temperatures above 70°C irreversibly denatures the protein.

Minor points:

Reviewer: Fig 2A: CD for protein samples is usually reported as molar ellipticity (theta) with units of deg*cm^2/dmol.

Author’s Response: SRCD measurements were previously presented in delta epsilon and are now converted and reported as such in molar ellipticity [(θ)m]. Using the formula Δε = (θ)m * Nr / 3298 (where, Delta Epsilon = Δε; (θ)m = Molar Ellipticity (θ)m; and Nr represents the number of amino acids in the protein = 564 :

Reviewer: Were replicate experiments performed for the thermal melt? If no, then the authors should confirm the reproducibility. Some data on reproducibility should be shown in the text or figures.

Authors Response: Thermal denaturation was conducted using Synchrotron radiation circular dichroism spectroscopy. A repeat of the thermal denaturation was conducted, however using conventional CD Jasco CD and Chirascan Cd spectrometers and a similar denaturation patterns were observed. The thermal melts results from two different sets of equipment and experimental set up with 3 scans averaged showing that the thermal melt is reproducible.

Reviewer: The folded fraction (y-axes) in Figures 2B&C is not well-defined because it is not clear whether 800C represent the fully denatured baseline. Also, because it is not whether the folding is cooperative or multi-state it is not clear how to convert the CD signal into a fraction folded value. I would advise plotting the y-axes as the raw CD signal.

Authors Response: The folded fraction represents the proportion of properly folded protein at a given temperature or concentration of denaturant. The following statement from the Methods section clarifies how this assay was conducted, “The CD spectral measurements were expressed as ratio of signal recorded at a particular temperature compared to the SRCD signal recorded at 10 °C. This facilitated estimation of the folded protein fraction of the protein at the respective temperature using as previously described protocols [34; 35].” The cited reference papers have details on the functions that were used to calculate the folded fraction as follows;

The following statements were included in the methods to clarify the conversion to folded fraction, “The folded state of the proteins at any given temperature was determined as follows (Misra and Ramachandran, 2009):

([θ]t – [θ]h) / ([θ]l – [θ]h) Equation 1

Where (θ)t is the molar ellipticity at any given temperature, (θ)h at highest temperature, and (θ)l at lowest temperature, respectively.”

“The folded state of the proteins at each urea concentration, the following equation (Eq. 1) modified to:

([θ]u - [θ]h) / ([θ]l - [θ]h)

Where [θ]u is the molar ellipticity at any given urea concentration, [θ]h at highest urea concentration, and [θ]l at lowest urea concentration, respectively.”

Reviewer: SAXS analysis of Hop has been performed in other studies in addition to the Rohl 2015 study (for example Onuoha et al. JMB 2008). It may be helpful to briefly discuss how your SAXS results compares with previous studies.

Authors Response: The SAXS results for PfHop have been compared with those of other Hop homologues and also discussed accordingly. The following statements were included, “In order to gain further insight into the structure of PfHop, we determined its low-resolution structure in solution using SAXS (Figure 3). The X-ray scattering curve (Figure 3A), the Kratky plot (Figure 3B), and the distance distribution function (Figure 3C) together indicate that PfHop is an elongated protein with a maximum dimension of approximately 24 nm (Table 1). PfHop consists mostly of folded parts connected by flexible linkers. Thus, as expected, the TPR domains likely are arranged like pearls on a string. The distance distribution function (Figure 3C) indicates at least two stable domains with maxima at ~3 and ~5 nm within the Dmax of 240 Å . The Dmax obtained for PfHop falls within the range obtained for other Hop homologues; 180 Å for LbHop [42], 193 Å for Hop [43], 230 Å for PfHop [46] and 260 Å for STI1 [20]. Altogether, these values confirm Hop to generally assume an extended conformation across species. An ab initio dummy residue model calculated using GASBOR (Figure 3D) is consistent with the above data and shows an excellent fit to the experimental data (Figure 3) with a χ2 value of 1.06. The model consists of an elongated shape with some more compact regions, as observed for STI1 [20]. This model visually fits perfectly to crystal structures of human and yeast Hop TPR1 (1ELW, [39]) as well as that of the TPR2AB (3UQ3, [23]) domain (Figure 3D).”

“Indeed, the low-resolution solution structure determined by SAXS shows that PfHop is a highly elongated and multidomain protein. This agrees with several previous independent studies [20; 42; 43; 46]. Notably, we observed that the folded domains of PfHop are organised like beads on a string. This is consistent with the predicted concave nature of its predominantly α-helical TPR motifs [18]. TPR motifs of human Hop have been described to occur as grooves into which the C-terminal EEVD motifs of Hsp90 and Hsp70 bind in extended form [39]. Our PfHop SAXS data is consistent with this proposed model.”

Reviewer: The discussion cites literature showing Hsp90/Hsp70 directly interacting in the absence of Hop. The ER-specific Hsp70/Hsp90 (BiP/Grp94) also show a direct interaction (see Sun et al. JBC 2019).

Authors Response: The following statement was added to the discussion citing recent literature, “Interestingly, Hsp70 and Hsp90 resident in the cytosols of E. coli and yeast as well as their homologs localized to mouse ER were shown to interact directly independent of Hop mediation [11; 12; 13; 14].” Reference 14 represents work by Sun et al., 2019 which we now included.

Reviewer #2: In the manuscript, Makumire and colleagues use a number of biophysical techniques to analyse the Plasmodium falciparum orthologue of the Hsp70/Hsp90 co-chaperone, Hop. The authors produced the protein recombinantly in E.coli as a his-tag fusion and purified it using IMAC and ion exchange chromatography. The purified protein subsequently underwent partial biophysical characterisation using CD/SRCD, SAXS and tryptophan fluorescence. They conclude that PfHop is an elongated monomer comprised mostly of alpha helical secondary structure. In addition, they conclude that PfHop is unstable at temperatures above 40 °C, while its partner protein PfHsp70-1 is stable at much higher temperatures.

Overall the manuscript is straightforward and the data presented are consistent with previous reports, and perhaps not surprising given the sequence similarity and molecular modelling of the PfHop structure, as well as our understanding of the structural and biophysical features of Hop from other organisms. This study provides experimental data to support bioinformatics models and demonstrate that structurally PfHop is similar to Hop from other organisms. A range of appropriate biophysical methods are used in the study, and the experiments appear to have been performed appropriately. Perhaps one limitation is that all of the analyses were conducted with a single concentration of PfHop.

Authors Responses: As this is a follow-up study using optimized protocols such as work from Gitau et al.,2012 [18]; Zininga et al., 2015 [19]; among other studies on the same/related proteins, the current protocol was thus guided by guidelines from such work. However, for distinct assays, we used protein concentrations that were appropriate for each assay as outlined in the methods section. Below we highlight extracts of some of the assays, highlighting protein concentrations used:

1. SRCD assays: “PfHop at a concentration of 0.5 mg/ml dialysed in buffer D (10 mM K3PO4, pH 7.0, 150 NaF) was analysed using a 98.56 µm path length round cell cuvette (Suprasil, Hellma Analytics, Germany) at a constant temperature of 10°C.”

2. SEC/SLS: 100 µg of PfHop in buffer C was injected into the column using a flow rate of 0.5 ml/min. BSA and ovalbumin were used as molecular-weight controls. The molecular weight of PfHop was determined based on the measured light scattering at three different angles and the refractive index using the ASTRA software version 6.1.5.22 (Wyatt Technology, Germany).

3. SAXS analyses: PfHop (2.2 mg/ml) and buffer samples were exposed to X-rays with a wavelength of 1.240 Å for 0.045 s. Pre-processed data were further analysed with the ATSAS software package [27].

Reviewer: This study is very similar to another one from the Borges lab (doi: 10.1016/j.bbapap.2019.140282.) which has just been published. In this recent paper, the group describes the biophysical characterisation of PfHop, including a number of similar or identical methods to this study (SAXS, tryptophan fluorescence, thermal unfolding and AUC). The fact that this recent paper is so similar should not prevent publication of the current study, but it does provide a good comparison for data generated in two independent labs. The PfHop study is very recent and hence it is possible that this paper may not have been identified prior to submission which is why it is not included. Nevertheless, this study should be an essential comparison to the current manuscript.

Authors Response: The findings from this study have now been compared to the recent PfHop paper (Silva et al., 2019 [46]) and discussions made accordingly in the various sections. Changes have been tracked.

Reviewer: The authors have been measured in their interpretation, and in my opinion, could perhaps improve the depth of comparison of their data to other key reports on biophysical characterisation of Hop orthologues without over-stating conclusions. The recent reports on direct interactions between Hsp70 and Hsp90 in eukaryotes needs to be given more priority and included in the introduction, not only the discussion. These studies redefine our understanding of the role that Hop plays in the Hsp70-Hsp90 complex. It is clear Hop is no longer essential for interaction in eukaryotes, although this does not mean it is not required under specific conditions. Therefore, it is not necessarily completely unexpected or surprising that PfHsp70 and PfHsp90 may be able to directly interact in the absence of PfHop.

Authors Responses: The data has been compared to other previous studies characterizing various Hop homologues. The direct interaction of Hsp70/Hsp90 was revisited and aspects included in the introduction. The introduction now reads as, “Stress inducible protein 1 (STI1) was first described in mouse [10], and now also known as Hsp70-Hsp90 organizing protein (Hop), acts as a module that allows Hsp70 and Hsp90 to interact stably, thereby facilitating substrate transfer from Hsp70 to Hsp90. Interestingly, there are recent findings that redefine our understanding of the role that Hop plays in the Hsp70-Hsp90 complex. Several studies have reported the direct interactions between Hsp90 and Hsp70 (Nakamoto et al., 2014; Kravats et al., 2017; 2018, Sun et al., 2019). Using Hsp90 and Hsp70 from bacteria and yeast, direct Hsp90/Hsp70 interaction was reported to occur via a region in the middle domain of Hsp90 (Nakamoto et al., 2014; Kravats et al., 2017; 2018). The ER Hsp70/Hsp90 (BiP/Grp94) were also shown to interact directly in a nucleotide dependent manner (Sun et al., 2019). Given that there is no Hop homolog in E. coli, a direct association between Hsp90 and Hsp70 in E. coli is important (Genest et al., 2016). The Hop gene is not essential in yeast (Reidy et al., 2018), Trypanosoma cruzi and Trypanosoma brucei although in the absence of Hop certain functions are affected (Schmidt et al., 2018). Hop may not be essential in some organisms but may be required under certain conditions. This might explain the need for Hsp90/Hsp70 direct interaction (Nakamoto et al., 2014). It remains to be investigated whether this direct interaction is conserved among species. Hop has been proposed as a potential drug target (Gitau et al., 2012; Zininga et al., 2015b). However, this would only apply in cases where Hop is essential for example in cancer (Röhl et al., 2014) and Leishmaniasis (Morales et al., 2010; Hombach et al., 2013).

Hop is a conserved and stress inducible protein that possesses three tetratricopeptide repeats (TPR): TPR1, TPR2A and TPR2B [10]. Both Hsp70 and Hsp90 interact with Hop via the C-terminal EEVD motif, present in the two molecular chaperones [1119; 23; 12]. Hop interacts with Hsp70 and Hsp90 via its TPR1 and TPR2A domains, respectively [1123]. While for a long time the role of the TPR2B domain of Hop has remained largely elusive, it is now thought that Hsp70 first binds to the TPR1 domain of Hop before switching to the TPR2B domain to facilitate substrate transfer to Hsp90 [20; 23].’’

Reviewer: PfHop is proposed to be instable at temperatures above 40 °C, which has implications for the PfHsp70-PfHsp90 chaperone complex during fever in malaria (where temperatures can reach this temperature). However, the conclusion of instability above 40 °C on the data presented is subjective at best. The authors should calculate the Tm which would give a more direct and comparable temperature stability. In addition, the current discussion fails to explicitly compare this with that reported for human Hop (in the region of 52 degrees C) as indicated by the study from the Regan group. This is important since the implication is that human Hop may be more stable than PfHop, which could imply biochemical differences between the two chaperone systems despite high sequence and structural similarity. In addition, the stability studies have been conducted in vitro and one needs to be cautious in directly extrapolating findings to an in vivo scenario where the protein may behave differently due to the environment. While I think the conclusion can be made, this aspect is not highlighted at all in the manuscript.

Authors Response: The PfHop Tm is the temperature at which 50 % of the protein is folded. We already have a folded fraction curve (Figure 2B shown as the temperature transitions that the protein undergoes during thermal unfolding. The calculated Tm for the protein is 50.8 °C and we prefer going with the thermal transitions of the protein unfolding.

Reviewer: What is the relevance of the data shown in Fig 2D? (now 2E) How this relates to the rest of the analysis was not clearly articulated to me.

Authors Response: Figure 2D shows the tertiary structure chemical perturbation of PfHop in the presence of denaturants (urea and guanidine chloride). This was monitored by tryptophan fluorescence to mirror the chemical perturbations observed in secondary structure analysis using CD spectra in Figure 2D.

Reviewer: It may be better to include Fig 3D as its own figure so that it can be made larger.

The SAXS results need to be compared to the studies from the Jackson lab (Onuoha et al J Mol Biol. 2008 Jun 13; 379(4):732-44), who did SAXS on human Hop-Hsp90 complexes and is currently not referenced in the manuscript, and from the Borges lab who have done this (and other biophysical characterisation) on both LmHop (doi: 10.1016/j.abb.2016.04.008.) and PfHop.

Authors Response: The SAXS data for PfHop has been compared with other SAXS studies on various Hop homologs as suggested.

Reviewer: How confident are the authors of the SEC-MAL data which appeared to consistently over-estimate the molecular weight of proteins studied? There are other studies on BSA at least which give a molecular weight at 64 kDa?

Authors Response: We are conscious of the limitations of the SEC-MAL data and do discuss this in our MS.

Reviewer: There are some minor missing articles and inconsistencies e.g. Tpr vs TPR in the manuscript that can be easily corrected with appropriate proofreading.

Authors Response: Inconsistencies were identified and rectified as in, “Human Hop TPR1 (1ELW; 0) and bakers’s yeast TPR2AB domains (3QU3; 11) were manually fitted in the ab initio envelope using PyMOL 2.3.2 (Schrödinger, USA). Any other minor inconsistencies were corrected in the text and highlighted through the track changes option.

Reviewer: A minor final point, the abstract makes reference to ‘select number of cellular proteins required for cyto-protection……’. To the best of my knowledge (and I could of course be wrong), there has been limited characterisation of bona fide chaperone clients in malaria and hence, while this statement is likely true, has it been experimentally verified?

Authors Response: The statement was reworded to “The cooperation of heat shock protein (Hsp) 70 and 90 is thought to facilitate folding of select group of cellular proteins that are crucial for cyto-protection and development of the parasites”.

Reviewer: The authors are encouraged to deposit the SAXS data in the SASBDB and link the accession number to the manuscript.

Authors Response: Thank you for this suggestion. We are considering depositing the data in the SASDB

Attachment

Submitted filename: Response to Reviewers 19 March 2020.docx

Decision Letter 1

Didier Picard

6 Apr 2020

Biophysical analysis of Plasmodium falciparum Hsp70-Hsp90 organizing protein (PfHop) reveals a monomer that is characterised by folded segments connected by flexible linkers

PONE-D-19-33340R1

Dear Dr. Shonhai,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at https://www.editorialmanager.com/pone/, click the "Update My Information" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

With kind regards,

Didier Picard

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Didier Picard

9 Apr 2020

PONE-D-19-33340R1

Biophysical analysis of Plasmodium falciparum Hsp70-Hsp90 organising protein (PfHop) reveals a monomer that is characterised by folded segments connected by flexible linkers

Dear Dr. Shonhai:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

For any other questions or concerns, please email plosone@plos.org.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Didier Picard

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig. Purification of PfHop by ion exchange and size exclusion chromatography.

    (A) SDS-PAGE analysis of the five samples collected from the main peak (lanes 1–5). Ion exchange chromatography of PfHop purification was monitored at 280 nm. Protein that bound to the column was then eluted under NaCl gradient. The five fractions obtained were pooled together for subsequent SEC analysis. (B) SDS-PAGE analysis of several fractions (lanes 1–11) of PfHop obtained by SEC are shown. (C) SDS-PAGE analysis of several fractions (lanes 1–12) of PfHop obtained by SEC are shown.

    (DOCX)

    S2 Fig. Mass spectrometry sequencing data for PfHop.

    (DOCX)

    S1 Table. PfHop secondary structure content.

    (DOCX)

    S1 Raw Images

    (PDF)

    Attachment

    Submitted filename: Response to Reviewers 19 March 2020.docx

    Data Availability Statement

    All relevant data are within the manuscript and its Supporting Information files.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES